Not Tagged
imugene
['solid tumor', 'imugene']
"the start of the cf-hnis trial in solid tumors is another milestone for the company's three technology platforms, with asco data from pd1-vaxx and her-vaxx supporting our expectations for those trials." price target 50c usd. new analyst coverage: $imu 
A clinical stage immuno-oncology biotech developing a range of new treatments seeking to activate the immune system of cancer patients. #FollowTheScience $IMU